DWP708 for Treating Epidermal Growth Factor Receptor Inhibitor Related Skin Toxicities

Summary

A Multi-center, Randomized, Double-blind, Placebo-controlled, Therapeutic Exploratory, Phase II Clinical Trial for the Efficacy Investigation and Safety Evaluation of DWP708 for Treating Rash Acneiform

Timeline

Start

2022-05-02

Primary completion

2023-12-05

Completion

2023-12-28

Drugs

Indications